Surmodics Inc (SRDX): Susan E Knight , director of Surmodics Inc sold 1,001 shares on May 27, 2016. The Insider selling transaction was reported by the company on May 31, 2016 to the Securities and Exchange Commission. The shares were sold at $22.71 per share for a total value of $22,733.71 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 8, 2016, Joseph J. Stich (VP, Bus Ops & GM, IVD) sold 1,000 shares at $18.63 per share price.On Mar 7, 2016, Timothy J. Arens (VP-Corporate Dev. and Strategy) sold 10,291 shares at $18.42 per share price.Also, On Aug 7, 2015, Charles W Olson (Senior VP & GM, Med Dev) sold 10,000 shares at $26.16 per share price.On May 26, 2015, Bryan K Phillips (SVP, Gen Counsel & Secretary) sold 7,293 shares at $25.25 per share price.
Shares of SurModics (SRDX) ended Friday, May 27, 2016 session in red amid volatile trading. The shares closed down -0.15 points or -0.66% at $22.49 with 52,858 shares getting traded. Post opening the session at $22.54, the shares hit an intraday low of $22.29 and an intraday high of $23.32 and the price vacillated in this range throughout the day. The company has a market cap of $293 M and the number of outstanding shares has been calculated to be 1,30,14,939 shares. The 52-week high of SurModics is $27.68 and the 52-week low is $17.45.
Company has been under the radar of several Street Analysts.SurModics is Reiterated by Barrington Research to Outperform and the brokerage firm has raised the Price Target to $ 30 from a previous price target of $27 .The Rating was issued on May 3, 2016.
SurModics Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates in two reportable segments: the Medical Device unit which is comprised of surface modification coating technologies to improve access deliverability and predictable deployment of medical devices as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device with end markets that include coronary peripheral and neurovascular and urology among others and the In Vitro Diagnostics unit which consists of component products and technologies for diagnostic immunoassay and molecular tests and biomedical research applications with products that include protein stabilization reagents substrates antigens and surface coatings.